Ozempic manufacturer Novo Nordisk said patient safety is a priority and “the benefit-risk profile of semaglutide remains unchanged” Ricardo Rubio/Europa Press via Getty Health officials in Europe are ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results